3 ms·
Sure, but as a result we don't have problems like thalidomide popping up every decade or so. There are benefits (and drawbacks) to having a much more stringent
by refurb 7y ago
Sure, but as a result we don't have problems like thalidomide popping up every decade or so. There are benefits (and drawbacks) to having a much more stringent approval process.
And probably worth adding that in public health emergencies, the FDA is more than willing to pull back on regulations in the interest of the public good.
- WalterBright 7y agoThalidomide was never approved for use in the US, and the heavy regulation came afterwards.
- jokowueu 7y agoIt's was never approved because of one person that was continually harrased if it wasn't for her it would have been approved . There were only 11 people responsible to review these new drugs . For crying out loud pcp was approved as an analgesic after using it on a few prisoners . FDA's stringent approval process is required
- WalterBright 7y ago> FDA's stringent approval process is required The downside of that is greatly reduced new drug development due to the expense, much more expensive drugs, and years of delay for the ones that are worked on. If you have a less popular disease, or can't wait years, you're out of luck.
- maxerickson 7y agoFDA has a special process and contributes funds to developing drugs for rare diseases: https://www.fda.gov/about-fda/office-clinical-policy-and-programs/office-orphan-products-development https://www.fda.gov/about-fda/office-clinical-policy-and-pro...
- vikramkr 7y agoDrug companies can charge whatever they want for less popular diseases. 45% of new approvals last year were for rare diseases. In the industry, rare diseases are sought out as ideal targets because of some regulatory advantages and market power. And there has been an obscene amount of money pouring into biotech and drug development over the past few years - probably one of the most active bull markets the industry has ever seen, with huge numbers of drugs in clinical trials and all sorts of fundamental new technologies under development. Industry's doing fine under the current regulatory regime, with this being one of the best times in history for development of rare disease drugs
- barry-cotter 7y agoYou can have a stringent safety process without having any efficacy process. The FDA has no incentive to approve drugs but plenty to deny them so delay is the order of the day. Delay in approving new effective drugs costs lives. The FDA has not shown any willingness to pull back on regulations during the current COVID crisis, nor have they historically shown any such willingness. Politicians have forced them to. They have never shown any organic willingness to relax regulations.
- HarryHirsch 7y agonor have they historically shown any such willingness You are uncritically repeating libertarian propaganda. The first Google hit for "FDA fast-track" is a press release from FDA for the approval of azidothymidine. Anyone who remembers the early days of the AIDS epidemic will know what kind of a wonder drug zidovudine was. Approval was in 1987; they discovered the HIV virus in 1984. 3 years from early discovery to market. A record, but AIDS was a public health emergency. Please do not repeat lies.
- WalterBright 7y ago> AIDS was a public health emergency. I.e. there was enormous political pressure put on the FDA to do something. If you suffer from a rare disease that is not on the 6 o'clock news every day, that's not likely to happen. (I remember those days - everyone was talking about AIDS, everyone was terrified of it.)
- HarryHirsch 7y agoThere is much more: https://www.fda.gov/drugs/nda-and-bla-approvals/fast-track-approvals https://www.fda.gov/drugs/nda-and-bla-approvals/fast-track-a... Just last year: triclabendazole for liver flukes. That's emphatically not political. From 2018: apalutamide, an androgen receptor antagonist. Prostate cancer doesn't nearly get the attention it deserves, not political but sorely needed. 2017: secnidazole, for bacterial vaginosis. Strange to see that there, given that there are sufficient nitroimidazoles at market already. No political pressure. Please, no reflexive regurgitation of libertarian propaganda directed against the FDA. They actually do their job.
- ravar 7y agoAvoiding another thalidomide would be all well if weren't for the fact that for many disorders the prognosis provided by standard practice is absolutely terrible.